Detalhe da pesquisa
1.
Modern developments in germline pharmacogenomics for oncology prescribing.
CA Cancer J Clin
; 72(4): 315-332, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302652
2.
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Lancet Oncol
; 25(1): 29-45, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38101433
3.
Implementation of pharmacogenomics testing for precision medicine.
Crit Rev Clin Lab Sci
; 61(2): 89-106, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37776898
4.
Implementation of pharmacogenomics into inpatient general medicine.
Pharmacogenet Genomics
; 33(2): 19-23, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729768
5.
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
Cancer
; 128(8): 1649-1657, 2022 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35090043
6.
Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care.
Pharmacogenet Genomics
; 32(3): 79-86, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570085
7.
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Oncologist
; 27(3): e223-e232, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274723
8.
Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial.
Anesth Analg
; 135(5): 929-940, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35213469
9.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 872-882, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991512
10.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(4): 525-537, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721560
11.
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Oncologist
; 26(11): e2042-e2052, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34423496
12.
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.
Pharmacogenomics J
; 21(6): 691-711, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34376788
13.
Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis.
Clin Exp Rheumatol
; 39(6): 1385-1393, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33506753
14.
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
Cancer
; 126(2): 432-443, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31581306
15.
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Cancer
; 126(20): 4485-4497, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757302
16.
Patient insights on features of an effective pharmacogenomics patient portal.
Pharmacogenet Genomics
; 30(9): 191-200, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33017129
17.
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
Breast Cancer Res Treat
; 181(3): 623-633, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32378051
18.
Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation.
Pharmacogenomics J
; 20(1): 126-135, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31506565
19.
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Cancer
; 125(4): 533-540, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30570744
20.
Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.
Pharmacogenet Genomics
; 29(2): 23-30, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30531378